Boehringer Ingelheim posts 11% rise in FY15 sales boosted by diabetes business
Boehringer Ingelheim reported 11% jump in sales for 2015 driven by its diabetes business and said for 2016 it sees a minor increase in net sales compared to last year given the low growth impetus in the pharmaceutical markets.
Germany’s second-largest drugmaker posted net sales of 14.8 billion euros, up over 11% year on year. Operating income also improved by 6% to 2.3 billion euros, the company said in a statement.
Excluding the generics business, which was sold at the beginning of 2016, currency-adjusted net sales rose by 5.3%, the company said.
Chairman Andreas Barner emphasised the need for innovation to propel future growth, and said: “The company is planning to invest around 11 billion euros in the international research and development of human pharmaceuticals over the next five years. Of this, 5 billion euros will go into pre-clinical research and development and 1.5 billion euros into cooperation with external partners.”
The family-owned company said it plans to considerably strengthen its market position despite the current market environment.
Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) …
German pharmaceutical company Boehringer Ingelheim (BI) and cell programming and biosecurity platform builder Ginkgo Bioworks …
The University of Oxford, the Earlham Institute, and global pharmaceutical companies Biogen and Boehringer Ingelheim …